CDC

Projektname
Interventions to increase screening and use of genetic services in young breast cancer survivors and at-risk female relatives: Randomized trial

Projektleitung
Maria C. Katapodi

INS-Projektteam
Maria. C. Katapodi
Chang Ming
Christos Nikolaidis (bis 2017)

Externe Projektpartner
USA: Northwestern University, Feinberg School of Medicine, Chicago (Debra Duquette) | Michigan Department of Health and Human Services, Cancer Genomics, Lansing (Beth Anderson) | Michigan Cancer Surveillance Program, Lansing (Glen Copeland)| University of Michigan, Ann Arbor: School of Nursing (Laurel Northouse, A.M Schafenacker, Victor Mendelson); School of Public Health (Nancy K. Janz, JS Roberts); School of Medicine (Sofia D. Merajver); Comprehensive Cancer Center (Kara J. Milliron); Department of Computational Medicine and Bioinformatics & Michigan Institute for Data Science (Ivo D. Dinov) | Ohio State University, College of Nursing, Columbus (Sonia A. Duffy) | Florida Atlantic University, Boca Raton, FL (Tarsha Jones)| The Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Harvard Medical School, Boston (Meghan Underhill) 

Ort der Datenerhebung
– community settings

Laufzeit
2012 bis ongoing

Projektbeschreibung
Hintergrund
Over the past decades, advances in screening, detection, and treatment have led to a significant reduction in the number of breast cancer deaths in the United States. More specifically, Michigan had a 40% decrease in mortality rates between 1990 (11.9 per 100,000) and 2009 (7.1 per 100,000) among young women diagnosed with breast cancer. However, the Comprehensive Cancer Control Plan for Michigan and the Healthy People 2020 objective is to further “reduce the female breast cancer death rate”. The study strives to accomplish this goal, specifically for female breast cancer survivors diagnosed at 25-45 years old and their female relatives who may also have an increased risk.2

Zielsetzung
The study has three aims: (1) To identify and survey 3000 female breast cancer survivors reported to the Michigan Cancer Surveillance Program who were diagnosed between the ages of 25-45 years (YBCS) and determine:(a) their breast cancer screening utilization; (b) perceived barriers and facilitators to screening; (c) willingness to participate in a small media, evidence-based intervention to increase breast cancer screening utilization; and (d) willingness to serve as a breast cancer screening advocate for their high-risk female relatives. (2) To identify and survey up to two unaffected first- and/or second- degree female relatives per breast cancer survivor and determine: (a) their breast cancer screening utilization; (b) perceived barriers and facilitators to screening; and (c) willingness to participate in a small media, evidence-based intervention to increase breast cancer screening utilization. (3) To compare the efficacy of two interventions on breast cancer screening utilization and other outcomes among YBCS and their high-risk female relatives

Design/Methode
This prospective randomized trial involved testing the efficacy of two printed interventions i.e., Targeted vs. Enhanced Tailored designed to increase screening and use of cancer genetic services. Participants were randomly assigned as family units (YBCS and her female relatives) to receive one of two intervention versions. Family units were mailed a self-administered baseline survey prior to receiving the intervention (Time 1). A self-administered follow-up survey was mailed to participants nine months post-intervention.

Erwarteter Nutzen / Relevanz
The study enhanced cancer prevention, control, and efforts toward public health genomics interventions. The two intervention versions provide a successful platform for implemention of public health genomic interventions.